WS #15173
Moderna shares reversed weakness, rising over 3% after a key technical signal at $186.46, suggesting short-term trader interest. Bristol-Myers Squibb received FDA approval for Camzyos as the first treatment for children with obstructive hypertrophic cardiomyopathy, a positive catalyst for its pipeline and the broader biotech sector. These are isolated positive developments within a broader risk-off environment.
Healthcare Sector Catalysts
Moderna shares reversed weakness, rising over 3% after a key technical signal at $186.46, suggesting short-term trader interest. Bristol-Myers Squibb received FDA approval for Camzyos as the first treatment for children with obstructive hypertrophic cardiomyopathy, a positive catalyst for its pipeline and the broader biotech sector. These are isolated positive developments within a broader risk-off environment.